AUTHOR=Feng Peng , Li Zhenqing , Li Yuchen , Zhang Yuelin , Miao Xingyu 

TITLE=Characterization of Different Subtypes of Immune Cell Infiltration in Glioblastoma to Aid Immunotherapy

JOURNAL=Frontiers in Immunology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.799509

DOI=10.3389/fimmu.2022.799509

ISSN=1664-3224

ABSTRACT=<p>Glioblastoma multiforme (GBM) has been identified as a frequently occurring adult primary brain cancer that is highly aggressive. Currently, the prognostic outcome for GBM patients is dismal, even with intensive treatment, and the median overall survival (OS) is 14.6 months. Immunotherapy, which is specific at the cellular level and can generate persistent immunosurveillance, is now becoming a promising tool to treat diverse cancers. However, the complicated nature of the tumor microenvironment (TME) makes it challenging to develop anti-GBM immunotherapy because several cell types, cytokines, and signaling pathways are involved in generating the immunosuppressive environment. Novel immunotherapies can illustrate novel tumor-induced immunosuppressive mechanisms. Here, we used unsupervised clustering analysis to identify different subtypes of immune cell infiltration that actuated different prognoses, biological actions, and immunotherapy responses. Gene cluster A, with a hot immune cell infiltration phenotype, had high levels of immune-related genes (IRGs), which were associated with immune pathways including the interferon-gamma response and interferon-alpha response, and had low <italic>IDH1</italic> and <italic>ATRX</italic> mutation frequencies. Gene cluster B, a cold immune cell infiltration subtype, exhibited a high expression of the <italic>KCNIP2</italic>, <italic>SCRT1</italic>, <italic>CPLX2</italic>, <italic>JPH3</italic>, <italic>UNC13A</italic>, <italic>GABRB3</italic>, <italic>ARPP21</italic>, <italic>DLGAP1</italic>, <italic>NRXN1</italic>, <italic>DLL3</italic>, <italic>CA10</italic>, <italic>MAP2</italic>, <italic>SEZ6L</italic>, <italic>GRIA2</italic>, and <italic>GRIA4</italic> genes and a low expression of immune-related genes, i.e., low levels of immune reactivity. Our study highlighted the complex interplay between immune cell infiltration and genetic mutation in the establishment of the tumor immune phenotype. Gene cluster A was identified as an important subtype with a better prognosis and improved immunotherapy response.</p>